The DOI matches its Crossref record; 255 of the 255 references it cites were found in a registry or an index.
Development of Immunotherapy Combination Strategies in Cancer
Open accessAbstract
Harnessing the immune system to treat cancer through inhibitors of CTLA4 and PD-L1 has revolutionized the landscape of cancer. Rational combination strategies aim to enhance the antitumor effects of immunotherapies, but require a deep understanding of the mechanistic underpinnings of the immune system and robust preclinical and clinical drug development strategies. We review the current approved immunotherapy combinations, before discussing promising combinatorial approaches in clinical trials and detailing innovative preclinical model systems being used to develop rational combinations. We also discuss the promise of high-order immunotherapy combinations, as well as novel biomarker and combinatorial trial strategies.Significance: Although immune-checkpoint inhibitors are approved as dual checkpoint strategies, and in combination with cytotoxic chemotherapy and angiogenesis inhibitors for multiple cancers, patient benefit remains limited. Innovative approaches are required to guide the development of novel immunotherapy combinations, ranging from improvements in preclinical tumor model systems to biomarker-driven trial strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–255 of 255
Lute, K. D., May, K. F., Lu, P., Zhang, H., Kocak, E., Mosinger, B., Wolford, C. C., Phillips, G. S., Caligiuri, M. A., Zheng, P., et al. (2005) · Blood · doi:10.1182/blood-2005-06-2298 · Cited by 118
Kodumudi, K. N., Weber, A. M., Sarnaik, A. A., & Pilon‐Thomas, S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200274 · Cited by 117
Bloom syndrome protein restrains innate immune sensing of micronuclei by cGAS
Gratia, M., Rodero, M. P., Conrad, C., Samra, E. B., Maurin, M., Rice, G., Duffy, D., Revy, P., Petit, F., Dale, R. C., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181329 · Cited by 116
Moreno, B. H., Mok, S., Comin-Anduix, B., Hu‐Lieskovan, S., & Ribas, A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1052212 · Cited by 106
Adusumilli, P. S., Zauderer, M. G., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Ngai, D. A., McGee, E., Chintala, N. K., Messinger, J., Cheema, W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2511 · Cited by 93
Gibney, G. T., Hamid, O., Lutzky, J., Olszanski, A. J., Mitchell, T. C., Gajewski, T. F., Chmielowski, B., Hanks, B. A., Zhao, Y., Newton, R. C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0562-8 · Cited by 88
Le, A. X., Bernhard, E. J., Holterman, M., Strub, S., Parham, P., Lacy, E., & Engelhard, V. H. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.4.1366 · Cited by 86
Harding, J. J., Patnaik, A., Moreno, V., Stein, M. N., Jankowska, A. M., de Mendizábal, N. V., Liu, Z. T., Koneru, M., & Calvo, E. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.8_suppl.12 · Cited by 86
Schwartz, H. S., & Grindey, G. B. (1973) · PubMed · Cited by 83
Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas
Wang, X., Waschke, B. C., Woolaver, R. A., Chen, Z., Zhang, G., Piscopio, A. D., Liu, X., & Wang, J. H. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0875 · Cited by 83
Peripheral blood CD34+ cells efficiently engraft human cytokine knock-in mice
Saito, Y., Ellegast, J. M., Rafiei, A., Song, Y., Kull, D., Heikenwälder, M. F., Rongvaux, A., Halene, S., Flavell, R. A., & Manz, M. G. (2016) · Blood · doi:10.1182/blood-2015-10-676452 · Cited by 81
Hooijkaas, A. I., Gadiot, J., Morrow, M., Stewart, R. A., Schumacher, T. N., & Blank, C. U. (2012) · OncoImmunology · doi:10.4161/onci.20226 · Cited by 80
Speranza, M. C., Passaro, C., Ricklefs, F. L., Kasai, K., Klein, S. R., Nakashima, H., Kaufmann, J. K., Ahmed, A.-K., Nowicki, M. O., Obi, P., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox139 · Cited by 78
Vinayak, S., Tolaney, S. M., Schwartzberg, L. S., Mita, M. M., McCann, G. A.-L., Tan, A. R., Wahner Hendrickson, A. E., Forero-Torres, A., Anders, C. K., Wulf, G. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1011 · Cited by 77
Reck, M., Liu, S. V., Mansfield, A. S., Mok, T. S. K., Scherpereel, A., Reinmuth, N., Garassino, M. C., Carpeño, J. D. C., Califano, R., Nishio, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz264 · Cited by 73
Choi, H., Deng, J., Li, S., Silk, T., Dong, L., Brea, E. J., Houghton, S., Redmond, D., Zhong, H., Boiarsky, J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.066 · Cited by 72
Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
Hong, D. S., Schöffski, P., Calvo, A., Sarantopoulos, J., de Olza, M. O., Carvajal, R. D., Prawira, A., Kyi, C., Esaki, T., Akerley, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3012 · Cited by 72
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Mao, W., Ghasemzadeh, A., Freeman, Z. T., Obradović, A., Chaimowitz, M. G., Nirschl, T. R., Emily, M., Yegnasubramanian, S., & Drake, C. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0758-y · Cited by 72
Nathan, P., Dummer, R., Long, G. V., Ascierto, P. A., Tawbi, H., Robert, C., Rutkowski, P. L., Леонов, О. В., Dutriaux, C., Mandalà, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2273 · Cited by 67
Self-citationKimpfler, S., Sevko, A., Ring, S., Falk, C. S., Osen, W., Frank, K., Kato, M., Mahnke, K., Schadendorf, D., & Umansky, V. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900609 · Cited by 66
O’Hara, M. H., O'Reilly, E. M., Mick, R., Varadhachary, G. R., Wainberg, Z. A., Ko, A. H., Fisher, G. A., Rahma, O. E., Lyman, J. P., Cabanski, C. R., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct004 · Cited by 66
Plimack, E. R., Rini, B. I., Stus, V. P., Gafanov, R. A., Waddell, T., Nosov, D., Pouliot, F., Soulières, D., Melichar, B., Vynnychenko, I. O., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.5001 · Cited by 65
de Lara, P. T., Cecconi, V., Hiltbrunner, S., Yagita∥, H., Friess, M., Bode, B., Opitz, I., Vrugt, B., Weder, W., Stolzmann, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1231 · Cited by 63
The Mouse Tumor Biology Database: A Comprehensive Resource for Mouse Models of Human Cancer
Krupke, D. M., Begley, D. A., Sundberg, J. P., Richardson, J. E., Neuhauser, S. B., & Bult, C. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0584 · Cited by 61
Kim, S.-H., Roszik, J., Cho, S.-N., Ogata, D., Milton, D. R., Peng, W., Menter, D. G., Ekmekçioglu, S., & Grimm, E. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1163 · Cited by 61
Self-citationLenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, K. Y. M., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.11 · Cited by 59
Wu, F. T. H., Man, S., Xu, P., Chow, A., Paez-Ribes, M., Lee, C. R., Pirie-Shepherd, S. R., Emmenegger, U., & Kerbel, R. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0888 · Cited by 58
Targeting adenosine A2A receptor antagonism for treatment of cancer
Congreve, M., Brown, G. A., Borodovsky, A., & Lamb, M. L. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1534825 · Cited by 56
Ascierto, P. A., Ferrucci, P. F., Stephens, R., Vecchio, M. D., Atkinson, V. G., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Giacomo, A. M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy289 · Cited by 52
Yu, E. Y., Massard, C., Retz, M. M., Tafreshi, A., Carles, J., Hammerer, P., Fong, P. C. C., Shore, N. D., Joshua, A. M., Linch, M. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.145 · Cited by 52
Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer
Le, X., Ferrarotto, R., Wise-Draper, T. M., & Gillison, M. L. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7590 · Cited by 52
Bendell, J. C., Ciardiello, F., Tabernero, J. M., Tebbutt, N. C., Eng, C., Bartolomeo, M. D., Falcone, A., Fakih, M., Kozloff, M. F., Segal, N. H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy208.003 · Cited by 50
Yuan, Z., Fromm, A., Ahmed, K. A., Grass, G. D., Yang, G. Q., Oliver, D. E., Dilling, T. J., Antonia, S. J., & Perez, B. A. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.029 · Cited by 49
Friedman, J., Morisada, M. V., Sun, L., Moore, E. C., Padget, M. R., Hodge, J. W., Schlom, J., Gameiro, S. R., & Allen, C. T. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0374-2 · Cited by 49
Yap, T. A., Krebs, M., Postel-Vinay, S. C., Bang, Y., El-Khoueiry, A. B., Abida, W. M., Harrington, K. J., Sundar, R., Carter, L., Álvarez, E. C., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32607-7 · Cited by 48
Self-citationTsai, A. K., Khan, A. Y., Worgo, C. E., Wang, L. L., Liang, Y., & Dávila, E. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0009 · Cited by 48
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Hierro, C., Matos, I. G., Martín-Liberal, J., de Olza, M. O., & Garralda, E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3694 · Cited by 45
Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer
Jin, M. H., Nam, A., Park, J. E., Bang, J., Bang, Y., & Oh, D. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.183 · Cited by 45
Sullivan, R. J., Moschos, S. J., Johnson, M. L., Opyrchal, M., Ordentlich, P., Brouwer, S., Sankoh, S., Meyers, M. L., & Agarwala, S. S. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct072 · Cited by 44
Taylor, M. H., Rasco, D. W., Brose, M. S., Vogelzang, N. J., Richey, S. L., Cohn, A. L., Richards, D., Stepan, D. E., Dutcus, C. E., Guo, M. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.6016 · Cited by 38
Istradefylline for the treatment of Parkinson's disease
Park, A., & Stacy, M. A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.643869 · Cited by 36
He, A. R., Yau, T. C. C., Hsu, C., Kang, Y., Kim, T., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.512 · Cited by 36
Kroon, P., Gadiot, J., Peeters, M. J. W., Gasparini, A., Deken, M. A., Yagita∥, H., Verheij, M., Borst, J. G., Blank, C. U., & Verbrugge, I. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1843-4 · Cited by 34
Garton, A. J., Seibel, S., Lopresti-Morrow, L., Crew, L., Janson, N., Mandiyan, S., Trombetta, E. S., Pankratz, S., LaVallee, T. M., & Gedrich, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0676 · Cited by 32
Lee, J. J., Sun, W., Bahary, N., Ohr, J. P., Rhee, J. C., Stoller, R. G., Marks, S. M., Lembersky, B. C., Beasley, H. S., Drummond, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3054 · Cited by 29
Caudana, P., Núñez, N. G., Rochère, P. D. L., Pinto, A., Denizeau, J., Alonso, R., Niborski, L. L., Lantz, O. J., Sedlik, C., & Piaggio, E. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0697 · Cited by 29
Burlion, A., Ramos, R. N., Pukar, K. C., Sendeyo, K., Corneau, A., Ménétrier‐Caux, C., Piaggio, E., Olive, D., Caux, C., & Marodon, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596005 · Cited by 26
Zaidi, N., Quezada, S. A., Kuroiwa, J. M. Y., Zhang, L., Jaffee, E. M., Steinman, R. M., & Wang, B. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14049 · Cited by 23
Hou, W., Yuan, Q., Yuan, X., Wang, Y.-X., Mo, W., Wang, H., & Yu, M. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0689-3 · Cited by 22
Miyashita, H., Mikami, T., Satoi, S., Cruz, C., & Galsky, M. D. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000339 · Cited by 17
Schvartsman, G., Ma, J., Bassett, R. L., Haydu, L. E., Amaria, R. N., Hwu, P., Wong, M. K., Hwu, W., Diab, A. K., Patel, S. P., et al. (2019) · Cancer · doi:10.1002/cncr.32454 · Cited by 15
Self-citationButler, M. O., Robert, C., Négrier, S., In, G. K., Walker, J. W. T., Krajsová, I., Atkinson, V. G., Hansson, J., Kapiteijn, E., Loquai, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps9599 · Cited by 12
Naing, A., Thistlethwaite, F. C., Spira, A. I., García-Corbacho, J., Randhawa, M., Eskens, F. A. L. M., O’Neil, B. H., Lavernia, J., Uboha, N. V., Hamid, O., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2513 · Cited by 11
Lebbé, C., Meyer, N., Mortier, L., Márquez‐Rodas, I., Robert, C., Rutkowski, P. L., Menzies, A. M., Eigentler, T., Ascierto, P. A., Smylie, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.057 · Cited by 9
Abstract IA38: Manipulating the gut microbiome to improve immunotherapy of melanoma
Davar, D., Vétizou, M., Dzutsev, A., Badger, J. H., McCullogh, J., Menna, C., Pagliano, O., Kirkwood, J. M., Trinchieri, G., & Zarour, H. M. (2019) · Cancer Immunology Research · doi:10.1158/2326-6074.cricimteatiaacr18-ia38 · Cited by 1
Research works printed but not linked: 16
- Davar D, 2018, A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma, J Immunother Cancer, 6, O21
- Lakhani N, 2018, The anti–LAG-3 antibody MK-4280 as monotherapy and in combination with pembrolizumab for advanced solid tumors: first-in-human phase 1 dose-finding study, J Immunother cancer, O114
- Weber, 2018, 1304TiP - A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM), Ann Oncol, 29, viii465, 10.1093/annonc/mdy289.060 · doi:10.1093/annonc/mdy289.060
- Hickingbottom, 2020, Preliminary safety and pharmacodynamic (PD) activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in a phase I dose escalation study of patients with selected advanced solid tumors, J Clin Oncol, 38, e15001, 10.1200/JCO.2020.38.15_suppl.e15001 · doi:10.1200/jco.2020.38.15_suppl.e15001
- Langowski, 2016, Abstract B057: the CD122-biased immunostimulatory cytokine NKTR-214 combined with checkpoint blockade leads to mobilization of antitumor immunity and synergistic activity, Cancer Immunol Res, 4, B057, 10.1158/2326-6066.IMM2016-B057 · doi:10.1158/2326-6066.imm2016-b057
- Zappasodi, 2019, Abstract PR01: mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients, Cancer Immunol Res, 7, PR01, 10.1158/2326-6074.CRICIMTEATIAACR18-PR01 · doi:10.1158/2326-6074.cricimteatiaacr18-pr01
- Reilley, 2019, Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors, J Clin Oncol, 37, TPS2669, 10.1200/JCO.2019.37.15_suppl.TPS2669 · doi:10.1200/jco.2019.37.15_suppl.tps2669
- Diab, 2018, 1245PD – Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): results from a multicenter, phase I/II study, Ann Oncol, 29, viii442, 10.1093/annonc/mdy289.001 · doi:10.1093/annonc/mdy289.001
- Komatsu, 2017, Abscopal effect of nivolumab in a patient with primary lung cancer, J Thorac Oncol, 12, e143, 10.1016/j.jtho.2017.05.004 · doi:10.1016/j.jtho.2017.05.004
- Zhang, 2018, ATMJAKPDL1 signaling pathway inhibition decreases EMT and metastasis of androgenindependent prostate cancer, Mol Med Rep, 17, 7045
- Ørskov, 2017, Activation of T cells specific to endogenous retroviral peptides: possible association with clinical response to azacitidine in myeloid malignancies, Blood, 130, 4243
- Alvarez, 2011, B16 murine melanoma: historical perspective on the development of a solid tumor model, 79, 10.1007/978-1-60761-968-0_4 · doi:10.1007/978-1-60761-968-0_4
- Gajewski, 2001, The p815 mastocytoma tumor model, Curr Protoc Immunol, 10.1002/0471142735.im2004s43 · doi:10.1002/0471142735.im2004s43
- Huang, 2018, Abstract A207: utilizing human OX40 knock-in mice (HuGEMMTM) to assess antitumor efficacy of OX40-agonistic antibodies, Mol Cancer Ther, 17, A207, 10.1158/1535-7163.TARG-17-A207 · doi:10.1158/1535-7163.targ-17-a207
- Zheng, 2018, Abstract A203: generation of human TIM3 knock-in mice for preclinical efficacy assessment of therapeutic antibodies, Mol Cancer Ther, 17, A203, 10.1158/1535-7163.TARG-17-A203 · doi:10.1158/1535-7163.targ-17-a203
- Food and Drug Administration H, 2020, Cancer clinical trial eligibility criteria: brain metastases guidance for industry, Fed Regist, 85, 41992
Cited by
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · Cancer Communications · doi:10.1002/cac2.12539 · Cited by 364
Yi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01155-6 · Cited by 163
Metadata
- Authors
- Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A.
- Venue
- Cancer Discovery
- Published
- 2021-04-02
- Volume
- 11
- Issue
- 6
- Pages
- 1368-1397
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3141168022
- Cited by
- 330
- References
- 255
- FWCI
- 17.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.